MDL Docket Established for Pfizer’s Ibrance Patent Infringement Cases

WASHINGTON, D.C. — A federal multidistrict litigation docket has been created for actions in which Pfizer is accusing various generic drug makers of infringing its patents for its metastatic breast cancer drug Ibrance (palbociclib).

In an Oct. 2 order, the Judicial Panel on Multidistrict Litigation centralized the litigation in the District of Delaware and appointed Judge Colm F. Connolly to oversee the docket, which currently consists of 13 actions.

Pfizer Inc., Warner-Lambert Company LLC, PF PRISM C.V., Pfizer Manufacturing Holdings LLC, and Pfizer PFE Ireland Pharmaceuticals Holding 1 B.V. filed the actions after the generic drug makers submitted Abbreviated New …